Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook

JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform

JMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $50.00.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $38.12 yesterday.

Mizuho Securities Downgrades Myriad Genetics (MYGN) to Neutral

Mizuho Securities downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Neutral with a price target of $32.00 (from $50.00).

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $38.12 yesterday.

Credit Suisse Downgrades Myriad Genetics (MYGN) to Underperform

Credit Suisse downgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Underperform with a price target of $30.00 (from $35.00) citing execution uncertainty following in-line Q2 but significantly lowered FY 2015 guidance.

Analyst V. Divan said the lower guidance appears mainly due to timing-related issues, but continued... More

Myriad Genetics (MYGN) CEO to Retire

Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly... More

Myriad Genetics (MYGN) halted news pending

Myriad Genetics (NASDAQ: MYGN) halted news pending